AstraZeneca is continuing to study AZD8205 as a monotherapy in dose optimization expansion cohorts of patients with ...

Imfinzi is a human monoclonal antibody that targets the PD-L1 protein, whereas Imjudo focuses on the CTLA-4 protein.

Fasenra is a monoclonal antibody that inhibits IL-5 alpha on eosinophils (a type of white blood cell), to induce cell death ...

Two of the world’s biggest drugmakers — AstraZeneca and MSD — have hailed progress in tackling hard-to-treat cancers, ...

London-listed AstraZeneca shares fell more than 5% on Tuesday after results from the company's lung cancer trials showed that ...

With a new production line, Sanofi aims to keep it and partner AstraZeneca’s drug Beyfortus in fully supply this RSV season.

AstraZeneca's Dato-DXd faces challenges in overall survival data but holds potential for approval with promising PFS benefits ...

Shares in AstraZeneca dropped nearly 5 per cent on Tuesday after its failure to hit a target in trials for a next-generation ...

The partners’ ADC didn’t significantly extend survival in lung cancer patients who were expected to benefit the most from ...

The trial compared the two treatments -- AstraZeneca's drug and chemotherapy ... belongs to a promising class known as antibody drug conjugates (ADC), which consist of tumour-seeking monoclonal ...

Mirvetuximab soravtansine was the first ADC to show efficacy as a therapy for platinum-resistant ovarian cancer. Despite high ...

AstraZeneca (AZN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sachin Jain ...